MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells by Chen, G K et al.
P-glycoprotein (P-gp) is a multidrug efflux pump encoded by the
MDR1 gene. P-gp is expressed in some normal and malignant
tissues, and associated with clinical multidrug resistance (MDR)
and poor prognosis in many cancer types (Ling, 1992; Gottesman,
1993; Sikic et al, 1997). Clinical trials using P-gp inhibitors such
as the cyclosporin analogue valspodar (PSC 833) combined with
chemotherapeutic agents are currently being carried out to reverse
or prevent clinical drug resistance (Fisher and Sikic, 1995).
Vinca alkaloids such as vinblastine are potent anti-tumour
agents and widely used in the chemotherapy of cancers. Cellular
mechanisms of resistance to vinca alkaloids include expression of
MDR1/P-gp, the mrp gene, alterations in tubulin or microtubule-
associated proteins, and alterations in the regulation of
programmed cell death or apoptosis (Cabral and Barlow, 1989;
Haber et al, 1995; Giannakakou et al, 1997; Dumontet and Sikic,
1999). Most cellular models of resistance to vinblastine were
established by step-wise selection of cancer cells up to very high
concentrations. Single-step selection and fluctuation analysis
provide a useful genetic tool to investigate the frequency and the
nature of various resistance mechanisms to cytotoxic agents (Luria
and Delbrück, 1943; Goldie and Coldman, 1979; Kendal and
Frost, 1988; Chen et al, 1994; Jaffrézou et al, 1994; Beketic-
Oreskovic et al, 1995; Dumontet et al, 1996).
In previous reports, we have identified the stochastic nature of
initial resistance mechanisms to etoposide, doxorubicin, pacli-
taxel, and doxorubicin in the presence of valspodar (PSC 833), in
the human sarcoma cell line MES-SA (Jaffrézou et al, 1994; Chen
et al, 1994; Beketic-Oreskovic et al, 1995; Dumontet et al, 1996).
In this study, we characterized the rate and mechanisms of resis-
tant cells derived from vinblastine single-step selection. Acquired
MDR1 expression in these single-step mutants was found in all
resistant clones and was associated with the initial resistant pheno-
type in these clones.
MATERIALS AND METHODS
Drugs and chemicals
Paclitaxel, etoposide, vinblastine, and doxorubicin were obtained
from the drug repository of the National Cancer Institute, NIH
(Bethesda, MD, USA). Valspodar (PSC 833) was a gift from
Novartis Pharmaceuticals (East Hanover, NJ, USA). [3H]-
Paclitaxel and [3H]-vinblastine were purchased from Amersham
Life Science Corporation (Arlington Heights, IL, USA). Other
chemicals were purchased from Sigma Chemical Company (St
Louis, MO, USA).
Cells and cell culture
The development, characterization, and culture of the human
uterine sarcoma cell line MES-SA and its multistep-selected MDR
variant Dx5 cells have been described (Harker et al, 1983; Harker
and Sikic, 1985). MES-SA cells have a pseudodiploid karyotype
of 45XX, which has remained stable over a 17-year period of
cultivation. Monolayer cultures of MES-SA cells are not growth
limited at low cell densities and have a plating efficiency greater
than 85% (Chen GK and Sikic BI, unpublished data). Therefore,
these human sarcoma cells are especially useful for fluctuation
analysis.
Luria–Delbrück fluctuation analysis
Subclonal MES-SA cells were expanded for fluctuation analysis.
Eight 25 cm2 tissue culture flasks (Corning Glass Works, Corning,
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NY, USA) were seeded with MES-SA cells at a low density (1000
cells per flask) and allowed to grow to near confluence (2 ´ 106
cells). The cells from each flask were seeded into separate 96-well
plates (1.7 ´ 106 cells per plate). After 4 h of incubation to ensure
active growth, cells were treated with 20 nM vinblastine.
Preliminary experiments had demonstrated that this concentration
of vinblastine resulted in approximately 5 logs of cell killing in
MES-SA cells. The drug-containing medium was changed every
other day for 14 days, and then replaced by drug-free medium.
Surviving colonies were allowed to grow for another 2 weeks and
were then individually harvested and propagated in drug-free
medium for further studies. The mutation rate was calculated
according to the method of Catcheside (Catcheside, 1951), from
the equation:
m = 2 ln 2(r2/N2 – r1/N1)/g
where m is the mutation rate per cell generation, r represents the
numbers of resistant colonies at times 1 and 2, N is the initial cell
number adjusted for plating efficiency, and g is the number of cell
generations.
In a control experiment, bulk populations of MES-SA cells
without expansion of the populations prior to drug exposure were
treated directly with vinblastine. In this experiment, six 96-well
plates were seeded with 1.7 ´ 106 cells per plate from a single
population of 1.0 ´ 107 cells and received identical exposure to
vinblastine as above.
Cytotoxicity assays and modulation of MDR by P-gp
inhibitors
Cytotoxicity assays and assessment of reversal of the MDR pheno-
type were performed using the 72 h MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] colourimetric assay as
previously described (Chen et al, 1994). The IC50 (drug concentra-
tion resulting in 50% inhibition of MTT dye formation compared
with the controls) was determined directly from semilogarithmic
dose–response curves.
Cell growth rate
The doubling times of MES-SA and the isolated clones were
determined by seeding cells in 96-well plates and incubating at
37°C for 4, 24, 48, and 72 h. The cellular growth rate was esti-
mated by the MTT colourimetric method. Population doubling
time (DTs) was calculated as previously described (Chen et al,
1994).
Flow cytometric analysis of P-gp expression
Retention of rhodamine 123 (Rh-123) was determined by a
FACS-II™ dual laser flow cytometer (Becton-Dickinson Corp,
Mountain View, CA, USA). Double labeling was performed with
Rh-123 and the monoclonal antibody UIC2 (Immunotech Corp,
Westbrook, ME, USA) (Chen et al, 1994). Cells were incubated
with or without 2 mM valspodar at 37°C, and stained with Rh-123
(0.1 mg ml–1) for 45 min, followed by 20 min drug efflux in the
presence or absence of 2 mM valspodar.
Western blotting and immunohistochemistry
The light-enhanced chemiluminescence Western blot protocol
(Amersham Life Science) was used for the detection of P-gp. Total
cell lysates were used for P-gp immunoblotting with the mono-
clonal antibody C219 (Signet Inc, Dedham, MA, USA) (Chen et
al, 1994; Beketic-Oreskovic et al, 1995). P-gp and LRP (p110)
expression were also assessed by immunocytochemistry, utilizing
the UIC2 and LRP-56 monoclonal antibodies (Caltag Laboratories
Inc, San Francisco, CA, USA) (Chen et al, 1994; Beketic-
Oreskovic et al, 1995).
Drug accumulation
Intracellular [3H]-vinblastine, [3H]-paclitaxel, [3H]-daunorubicin,
and [3H]-etoposide accumulations in the presence or absence of
the P-gp inhibitors valspodar and verapamil were quantitated
using radiolabeled drugs, and normalized to whole cellular protein
content (Beketic-Oreskovic et al, 1995; Chen et al, 1997).
Amplimers and RT-PCR
The amplimers and methodology for RT-PCR of MDR1, mrp, b-
tubulin isotypes, and rRNA have been previously documented
(Beketic-Oreskovic et al, 1995; Dumontet et al, 1996; Chen et al,
1997).
RESULTS
Fluctuation analysis and isolation of vinblastine-
resistant mutants
Table 1 presents the results of the fluctuation analysis experiment
in which populations of MES-SA sarcoma cells were selected with
vinblastine in a single step. The mean number of colonies
surviving drug exposure in the fluctuation test group was 14 per
cell population, each propagated from an initial seeding of 103
drug-sensitive cells, with a statistical variance of 107 from the
mean. In contrast, the mean number of colonies surviving drug
exposure among the control populations (derived from bulk
cultures of cells) was 16 per population, with a variance of 37
(Table 1). The larger ratio of variance relative to the mean number
of survivors in the fluctuation group (7.6 vs 2.3) supports the
hypothesis of spontaneous mutations conferring resistance to
vinblastine in these cells, rather than an effect of induction of
resistance by drug exposure. The mutation rate for vinblastine
resistance in this single-step selection was estimated to be 7 ´ 10–7
per cell per generation according to the method of Catcheside
(1951) (Table 1).
MDR phenotype and its reversal
A total of 13 clones which survived vinblastine exposure were
isolated, propagated and tested for resistance to the selecting agent
as well as to doxorubicin, paclitaxel and etoposide. These clones
included at least one from each of the eight original populations.
There was no detectable alteration in proliferation rates among
these clones compared to the parental cell line, which has a gener-
ation time of approximately 22 h (data not shown). All of the prop-
agated clones demonstrated an MDR phenotype (Table 2), typical
of  MDR1 expression. Thus, all clones showed marked cross-
resistance to paclitaxel (ranging from 50- to 200-fold). Cross-
resistance to paclitaxel was usually greater than to the selecting
agent vinblastine, and lower to doxorubicin and etoposide (Table
2). Five other clones were propagated (VL20-1.2, VL20-4.2,VL20-5.2, VL20-6.2, and VL20-8.2) and shown to have a similar
drug resistance phenotype to that of their related clones in Table 2
(data not shown). The resistance to vinblastine and paclitaxel in all
propagated clones was completely reversed by 2 mM valspodar.
All propagated clones maintained stable resistance to vinblastine
and paclitaxel over a 3-month period.
Rh-123 retention and potentiation by valspodar
The intracellular accumulation of the fluorescent P-gp substrate
Rh-123 was examined in eight resistant clones. All clones demon-
strated significantly decreased accumulation of Rh-123 (Figure 1),
with Rh-123 retention ranging from 14% to 56% compared to the
parental MES-SA cells (100%). Valspodar at 2 mM restored the
intracellular accumulation of Rh-123 to levels similar to the
parental cells, which do not express P-gp (Figure 1).
Accumulation of [3H]-vinblastine, [3H]-paclitaxel, and
[3H]-etoposide
The vinblastine selected clones demonstrated markedly reduced
intracellular accumulation of [3H]-vinblastine and [3H]-paclitaxel
relative to the wild-type MES-SA cells. Furthermore, this
decreased drug accumulation was reversed by the MDR
modulators valspodar and verapamil. In these experiments, 2 mM
valspodar completely sensitized the vinblastine-resistant pheno-
type to the parental MES-SA cell level (Figure 2). Valspodar at
2 mM was more effective as a modulator in these cells than 6 mM
verapamil, which only partially reversed the accumulation defects
for both vinblastine and paclitaxel (Figure 3). One clone showed
resistance to modulation by verapamil of the accumulation of
vinblastine and paclitaxel (Figure 3). In general, these results
suggest that a typical drug efflux mechanism associated with
reduced accumulation of total intracellular drugs was responsible
for cellular resistance to vinblastine in these clones.
Expression of MDR1 mRNA and P-gp
All examined clones expressed MDR1 mRNA transcripts and
functional P-glycoprotein, compared to the parental MES-SA cells
which do not express MDR1 (Figure 5A). P-gp expression and
function were analysed by double labeling of cells using the
monoclonal antibody UIC2 combined with Rh-123 accumulation.
Figure 4 demonstrates the association between P-gp expression
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Table 1 Fluctuation analysis of vinblastine-resistant MES-SA variants (14 days exposure in 20 nM vinblastine)
Fluctuation groupa Control group
Plate Total colonies Wells containing Total colonies Wells containing
per plate colonies per plate per plate colonies per plate
15 4 2 1 1 0
26 3 2 3 1 6
33 2 2 0 1 9
42 4 1 8 1 1 1 1
51 9 1 6 1 4 1 5
63 1 2 4 8 8
76 4 – –
81 6 1 0 – –
Total 110 81 97 79
Mean 14 10 16 13
Variance 107 69 37 17
Mutation rateb 7.0 ´ 10–7
aThe difference in the two groups was that a small number of cells (103) were seeded and grown separately in the
fluctuation group, according to Luria and Delbrück (1943), whereas the controls utilized bulk populations of cells
(1.7 ´ 106) from mass cultures, prior to selection with 20 nM vinblastine; bcalculated according to Catcheside (1951).
Table 2 Drug sensitivity phenotype of vinblastine-resistant MES-SA variants (fold resistancea)
Clones Vinblastine Paclitaxel Doxorubicin Etoposide
Controls
MES-SA 1 1 1 1
D´5 243 375 80 30
Single-step mutants
VL20-1.1b 13 65 6 6
VL20-2.1 17 71 12 6
VL20-3.1 14 125 14 2
VL20-4.1 70 172 38 5
VL20-5.1 18 200 4 2
VL20-6.1 54 53 17 9
VL20-7.1 144 167 4 4
VL20-8.1 36 50 10 3
aFold resistance was the ratio of the IC50s of the resistant cells to the parental MES-SA cells. The IC50s
were determined by the MTT cytotoxicity assay; bnomenclature of clones: e.g. VL20-1.1: VL =
vinblastine; 20 = 20 nM; and 1.1 = clone number 1 isolated from population number 1 of the fluctuation
analysis experiment. Each of the clones was propagated from a different population.Vinblastine resistance mechanisms 895
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and decreased retention of Rh-123 in the resistant clones
compared to parental MES-SA cells. There was a highly signifi-
cant correlation of P-gp/UIC2 expression with decreased Rh-123
accumulation among the nine tested clones (Figure 4D, r = 0.84,
P < 0.002). Expression of P-gp was confirmed in these clones by
Western blotting using the monoclonal antibody C219 (Figure
5B).
LRP and mrp expression
Expression of the major vault protein LRP was assessed by
immunocytochemistry, utilizing the LRP-56 monoclonal antibody.
The parental, drug-sensitive MES-SA cells stained positively for
LRP (p110). Vinblastine-selected variants had a similar degree of
LRP-56 staining compared to parental MES-SA cells (data not
shown). None of the vinblastine-selected clones had an increase in
mrp expression (Figure 6) or altered b-tubulin isotypes (M40, b4,
5b, and b9), assessed by RT-PCR (data not shown).
DISCUSSION
Fluctuation analysis provides a powerful approach to studying
the nature and rate of acquired resistance to anticancer agents,
although such studies are difficult and laborious in mammalian
cells (Luria and Delbrück, 1943; Goldie and Coldman, 1979;
Kendal and Frost, 1988; Chen et al, 1994; Jaffrézou et al, 1994;
Beketic-Oreskovic et al, 1995; Dumontet et al, 1996). The human
sarcoma cell line MES-SA is particularly suitable for such studies
because of its high plating efficiency, relative drug sensitivity, and
karyotypic and genetic stability over two decades of growth
(Harker et al, 1983; Chen and Sikic, unpublished data). Previously,
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Figure 1 Histogram of rhodamine-123 retention in clones of MES-SA cells
resistant to vinblastine. Rhodamine-123 (Rh-123) retention was assayed by
flow cytometry in MES-SA cells and vinblastine-resistant clones, with ( ) or
without (n) 2 mM valspodar
Figure 3 The effect of 6 mM verapamil on the accumulation of [3H]-
vinblastine and [3H]-paclitaxel in vinblastine-resistant clones of MES-SA cells.
The final concentration of both [3H]-vinblastine and [3H]-paclitaxel was 40 nM.
n = without verapamil; n n = with 6 mM verapamil
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Figure 2 The effect of 2 mM valspodar on the accumulation of [3H]-
vinblastine (A) and [3H]-paclitaxel (B) in vinblastine-resistant clones of MES-
SA cells. The final concentration of both [3H]-vinblastine and [3H]-paclitaxel
was 40 nM. n = without valspodar; n n = with valspodar896 GK Chen et al
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we have shown that activation of the MDR1 gene in MES-SA
sarcoma cells could be acquired by stochastic genetic events (Chen
et al, 1994; Dumontet et al, 1996). MDR1 activation was present in
all 13 mutants selected with doxorubicin (Chen et al, 1994), and in
four of nine (44%) selected with paclitaxel (Dumontet et al, 1996).
It has been shown that multiple mechanisms are involved in
cellular resistance to vinca alkaloids (Cabral and Barlow, 1989;
Haber et al, 1995; Giannakakou et al, 1997; Dumontet and Sikic,
1999). In order to investigate the nature or origin of acquired resis-
tance to vinca alkaloids in MES-SA cells, we used fluctuation
analysis to examine the potential diversity of resistance mecha-
nisms that may arise among eight parallel cell populations in a
single-step exposure to vinblastine. We found that all eight
mutants from separate parental cell populations acquired MDR1
expression and manifested the MDR phenotype characteristic
of P-gp.
In theory, if resistance was acquired by induced events or
directed mutations, the number of surviving colonies would be
expected to have a Poisson distribution, with the variance close to
the mean (Luria and Delbrück, 1943; Goldie and Coldman, 1979;
Kendal and Frost, 1988). In this study, the variance in number of
surviving colonies per plate was over 8-fold greater than the mean,
Figure 4 Flow cytometric analysis of rhodamine-123 retention and P-gp expression in MES-SA and vinblastine-selected mutants. Contour intensity maps (5%
probability plots) of the cells were obtained by two-colour flow cytometry using rhodamine-123 (x-axis) and the UIC2 monoclonal antibody for P-gp (y-axis). An
IgG2a isotype monoclonal antibody was used as an isotype control. (A) MES-SA cells stained with an IgG2a monoclonal antibody control; (B) MES-SA cells
stained with the UIC2 monoclonal antibody; (C) Clone VL20–7.1, stained with UIC2, representative of eight vinblastine-selected clones; (D) Correlation of
rhodamine-123 retention and P-gp expression by flow cytometry in clones of MES-SA cells resistant to vinblastine (l l). The linear correlation between Rh-123
accumulation and P-gp/UIC2 expression among various clones selected by vinblastine exposure is highly significant (r = 0.84, P < 0.002). The black dot (•)
represents the parental MES-SA cells
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nindicating a spontaneous event rather than direct induction of
MDR1 expression by drug exposure. These data are strong
evidence that a random mutational mechanism caused the cellular
resistance to vinblastine. The Luria–Delbrück test may be particu-
larly applicable for analysis of mutations due to single-step irre-
versible events, rather than two- or multiple-step genetic changes
such as gene amplification (Kimmel and Axelrod, 1994). The esti-
mated rate of mutation (7 ´ 10–7 per cell generation) conferring
resistance to 20 nM vinblastine in MES-SA cells is similar to that
which we observed for doxorubicin resistance (1.8 ´ 10–6) in the
same cells, and somewhat lower than that which has been
described for some gene amplification events in other cell lines,
1–7 ´ 10–5 per cell generation (Tlsty et al, 1989; Baker et al, 1974;
Crawford et al, 1983; Cole et al, 1976). It should be pointed out
that the spontaneous mutation rate is not always constant, but can
be highly dependent on the parental cell line, drug concentration,
and other experimental conditions (Boesen et al, 1994).
A significant level of MDR1 transcripts and P-gp expression
were verified in all tested clones which were initially cross-resis-
tant to the MDR-related drugs doxorubicin, vinblastine, paclitaxel,
and etoposide. There was some variability in the pattern of resis-
tance, which may reflect altered forms or post-translational regula-
tion of P-gp in these cells or clonal variation in other genes. In
addition to ruling out alterations in LRP and mrp expression, we
found no obvious alterations in tubulin content (data not shown) or
b-tubulin isotype expression in these mutants. Functional analysis
of P-gp by combined Rh-123 retention and UIC2 labeling was
performed in the vinblastine-resistant clones. The clones mani-
fested a typical MDR1 phenotype, including decreased intra-
cellular rhodamine 123, [3H]-paclitaxel, and [3H]-vinblastine
accumulations which were reversed by 2 mM valspodar (Figures
1–4; Table 2). Thus, these vinblastine-selected clones are pheno-
typically similar to the previously published MES-SA mutants
selected by doxorubicin with activation of MDR1 (Chen et al,
1994). The mechanisms of acquired MDR related to activation of
MDR1 are not well understood. The genetic mechanisms that regu-
late MDR1 expression acquired during drug selection may differ
from those responsible for constitutive expression, and these
single-step models may provide new insights into this question.
In conclusion, these data demonstrate that resistance to 20 nM
vinblastine in the human sarcoma cell line MES-SA is not induced
but arises spontaneously with an apparent mutation rate of 7 ´ 10–7
per cell generation. Vinblastine exposure selected predominantly
for MDR1-expressing variants. It is likely that these mutants arose
from one major event leading to an activation of MDR1. The
detailed nature of the MDR1 gene activation in these clones is
being investigated.
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blotting using the monoclonal antibody C219 as previously described (Chen
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controls respectively. Two representative vinblastine-selected clones are
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